Mesothelioma is a hard cancer to treat that is mainly caused by asbestos. People with this cancer typically do not live very long after diagnosis, but some people live longer than expected. A study recently published in the journal Toxics looked at people with mesothelioma and asbestos-caused lung cancer. All[…]
Mesothelioma
Altered CAR-T Cell Therapy for the Treatment of Mesothelioma
Immunotherapy is an innovative and groundbreaking way to treat cancer. It uses the immune system to fight and kill cancer cells. One immunotherapy treatment that is showing good results for certain cancers is called CAR-T cell therapy, which is able to target specific proteins on cancer cells. One of the[…]
GPC3/Mesothelin-CAR-γδT Cells Against Cancers
Primary Outcome Measures Number of Patients with Dose Limiting Toxicity Secondary Outcome Measures Percent of Patients with best response as either complete remission or partial remission. Median γδT cell persistence Inclusion Criteria 1. Patients with advanced cancer that expresses GPC3 or Mesothelin protein; 2. Life expectancy >12 weeks; 3. Adequate[…]
ADI-PEG 20 is Being Tested on Non-Epithelioid Mesothelioma
Polaris Group recently announced an application for a rolling submission of a new mesothelioma treatment. The Biologic License Application is the first step in becoming approved by the Food and Drug Administration. The treatment, known as ADI-PEG 20, is for the use on non-epithelioid mesothelioma patients alongside pemetrexed and platinum[…]
Induction Chemo+Immunotherapy in Resectable Epithelioid and Biphasic Pleural Mesothelioma (CHIMERA Study) (CHIMERA)
Primary Outcome Measures Primary endpoint – To evaluate the activity of neo-adjuvant treatment by the determination of pathological complete response rate (pCR) Secondary Outcome Measures Secondary endpoint – To further evaluate the activity of neo-adjuvant treatment in terms of major pathological response. Secondary endpoint – To further evaluate the activity[…]
Pembrolizumab and Chemotherapy Improve Survival in Patients
Pleural mesothelioma, a cancer mainly caused by asbestos, is a hard cancer to treat. Diagnosis usually occurs when it is in a late stage, leading to limited treatment options. New clinical trials are always being performed to try to find a new treatment approach that could possibly extend the lives[…]
Checkmate743 Showed Higher Toxicity in a Real World Setting
A group of Australian patients receiving Checkmate743 therapy saw higher levels of toxicity compared to CheckMate743 clinical trial patients. Checkmate743 consists of a dual treatment of ipilimumab and nivolumab and is the standard of care for patients with unresectable pleural mesothelioma. Unresectable means patients are not able to receive surgery[…]
A New Biomarker Could Help Doctors Diagnose Mesothelioma
A new biomarker has been found for the diagnosis of mesothelioma by scientists in Japan. Information from this research could revolutionize how mesothelioma is diagnosed and treated in the future. Mesothelioma is a hard cancer to diagnose because it shares symptoms with other cancers. Cancers it can look like include[…]
Johnson & Johnson Will Try to File for Bankruptcy for a Third Time
Johnson & Johnson may try to file bankruptcy for a third time to address its talc liabilities. The company has failed twice before but is looking again to file for bankruptcy under a different corporate structure. There are around 51,000 lawsuits claiming that people who used Johnson & Johnson’s talc-based[…]
Chemoimmunotherapy Benefits Pleural Mesothelioma Patients
Results from a phase 3 clinical trial were recently published in the Journal of Clinical Oncology showing that a combination of chemotherapy and immunotherapy for mesothelioma improves patients’ survival more than chemotherapy alone. Researchers combined Keytruda, or pembrolizumab, with platinum and pemetrexed chemotherapy. The overall response rate for patients receiving[…]
